- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05283382
Cannabidiol Effects on Learning and Anxiety
November 27, 2023 updated by: Robert Astur, University of Connecticut
To examine the extent to which Cannabidiol (CBD) enhances fear conditioning extinction in college undergraduates who show elevated social anxiety.
Undergraduates who display elevated social anxiety on standard assessments will be recruited at the University of Connecticut.
All participants will be put in a standard fear conditioning paradigm where they are conditioned to fear a face that occasionally is followed by a shock to their wrist.
The other face never is paired with a shock.
After everybody learns this, half of the participants will receive 600 mg CBD Isolate Gel Capsules one time, and the other half will receive a placebo dose.
Participants will then be presented with the faces with no shocks, and the rate and duration of extinction as measured by electrodermal response as well as subjective fear ratings via a visual analogue scale will be examined.
It is hypothesized that participants that receive CBD will display enhanced extinction compared to the placebo group, as evidenced by reduced electrodermal response and reduced visual analogue fear ratings.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
160
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Robert Astur, PhD
- Phone Number: 18609851239
- Email: robert.astur@uconn.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18-50 years of age
Exclusion Criteria:
- Difficulties seeing a computer screen
- Anyone currently taking CBD within the last 24 hours.
- Anyone using any cannabis product within the last 24 hours.
- Heart problems or heart disease
- A neurological disorder such as epilepsy, stroke, multiple sclerosis, tumor, vascular malformations, aneurysm
- Are currently pregnant or breast-feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cannabidiol
600 mg Cannabidiol Isolate Gel Capsules / participant.
One-time dose.
|
Participants will receive a one-time dose of 600 mg Cannabidiol Isolate Gel Capsules in the form of six 100mg capsules.
|
Placebo Comparator: Placebo
Same number of placebo capsules / participant.
One-time dose.
|
Participants will receive a one-time dose of placebo capsules in the form of six capsules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electrodermal activity
Time Frame: 20 minutes
|
Electrodermal response as measured by galvanic skin response electrodes that are attached to two of the fingers via sticker electrodes.
These passively measure the conductance of the sweat glands on the fingers.
|
20 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
February 1, 2024
Primary Completion (Estimated)
December 30, 2024
Study Completion (Estimated)
February 1, 2025
Study Registration Dates
First Submitted
February 23, 2022
First Submitted That Met QC Criteria
March 7, 2022
First Posted (Actual)
March 17, 2022
Study Record Updates
Last Update Posted (Actual)
November 28, 2023
Last Update Submitted That Met QC Criteria
November 27, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H21-0159
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety and Fear
-
KK Women's and Children's HospitalRecruitingAnxiety | Pregnancy Related | Fear | Fear of Childbirth | Anxiety and FearSingapore
-
University of PennsylvaniaActive, not recruiting
-
Karadeniz Technical UniversityCompletedAnxiety and FearTurkey
-
Indira Gandhi Institute of Dental ScienceUnknown
-
Laureate Institute for Brain Research, Inc.National Institute of Mental Health (NIMH); California Institute of TechnologyRecruitingDepression | Anxiety Disorders | Fear | Depression, Anxiety | Anxiety and Fear | Anxious DepressionUnited States
-
Maltepe UniversityRecruitingAnxiety and FearTurkey
-
Aga Khan UniversityRecruiting
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Recruiting
-
Aydin Adnan Menderes UniversityCompletedAnxiety | FearTurkey
-
Government Dental College and Hospital, IndiaLata Medical Research Foundation, NagpurCompleted
Clinical Trials on Cannabidiol Oral Product
-
Medical University of ViennaCompleted
-
Zin W MyintCompletedProstate Cancer | Prostate Adenocarcinoma | Prostate Cancer RecurrentUnited States
-
Rabin Medical CenterUnknownCannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell TransplantationGraft Versus Host DiseaseIsrael
-
Radius Pharmaceuticals, Inc.TerminatedChildhood Absence EpilepsyUnited States
-
INSYS Therapeutics IncTerminatedSpasms, InfantileUnited States
-
University of Colorado, DenverRecruitingAutism Spectrum DisorderUnited States
-
MultiCare Health System Research InstituteNo longer availableRefractory Epilepsy
-
Radius Pharmaceuticals, Inc.Benuvia Therapeutics Inc.TerminatedChildhood Absence EpilepsyUnited States
-
Colorado State UniversityInstitute of Cannabis ResearchCompleted
-
Meyer Children's Hospital IRCCSNot yet recruitingEpilepsy | Rare Diseases